New Treatment Center for ZEVASKYN Gene Therapy
Abeona Therapeutics Inc. (NASDAQ: ABEO) has teamed up with Children's Hospital Colorado to establish a new Qualified Treatment Center (QTC) for ZEVASKYN (prademagene zamikeracel) gene-modified cellular sheets. This innovative therapy has gained FDA approval and is specifically designed to treat debilitating wounds in both adult and pediatric patients suffering from recessive dystrophic epidermolysis bullosa (RDEB).
Commitment to Patient Care
Children's Hospital Colorado, based in Aurora, is recognized for its pioneering efforts in the care of patients with epidermolysis bullosa (EB). The hospital recently completed QTC start-up activities that will enable it to begin identifying patients who can benefit from the ZEVASKYN treatment. With the help of cutting-edge treatments and a focus on patient-centered care, the hospital aims to significantly improve the quality of life for those affected by RDEB.
Expert Insights on ZEVASKYN
Dr. Anna L. Bruckner, Co-Director of the EB Clinic at the hospital, expressed enthusiasm over the new partnership, highlighting the importance of having long-lasting treatment options available to patients. "This development is an exciting opportunity to enhance the quality of life for our patients dealing with this challenging condition," she stated.
Industry Recognition
The epidermolysis bullosa program at Children's Hospital Colorado is lauded as a center of excellence by debra of America, a leading patient advocacy group. In addition to its clinical offerings, the hospital participates in the EB Clinical Research Consortium, where it is continuously engaging in innovative research that seeks to advance treatment options for rare diseases like RDEB.
About ZEVASKYN and Its Application
ZEVASKYN is recognized as the first autologous cell sheet-based gene therapy targeting RDEB. By utilizing a patient’s own skin cells, this groundbreaking therapy incorporates the COL7A1 gene through an advanced modification process, allowing for the production of type VII collagen necessary for skin integrity. The therapy has shown promising results in healing wounds and reducing pain, offering hope to patients who often deal with severe complications due to their condition.
Patient Support Services
Abeona offers a comprehensive patient support program known as Abeona Assist™, which is designed to help patients navigate their treatment journey. This program includes assistance with understanding insurance benefits, exploring financial aid options, and providing logistical support to patients undergoing treatment.
The Challenge of RDEB
RDEB is a rare condition characterized by painful skin blisters and wounds that can significantly impact a person’s health and quality of life. Individuals with RDEB have a genetic defect in the COL7A1 gene, which is critical for producing the collagen needed to anchor skin layers together. The absence of this crucial protein leaves skin vulnerable and prone to injury.
Understanding Safety and Efficacy
While ZEVASKYN offers exciting new treatment possibilities for RDEB, potential safety concerns must also be acknowledged. Serious allergic reactions, such as anaphylaxis, can occur following treatment, and there may be long-term risks associated with cancer development due to the nature of gene therapy. Ongoing monitoring of patients is essential to manage these risks effectively.
About Abeona Therapeutics
Abeona Therapeutics Inc. is at the forefront of biopharmaceuticals, specializing in the development of cell and gene therapies for serious health conditions. With a fully integrated manufacturing facility in Cleveland, Ohio, Abeona is committed to producing cutting-edge treatments, including ZEVASKYN, while continuously exploring new avenues for addressing greater medical needs.
Frequently Asked Questions
What is ZEVASKYN?
ZEVASKYN is an autologous cell sheet-based gene therapy approved for treating wounds in patients diagnosed with recessive dystrophic epidermolysis bullosa (RDEB).
How does ZEVASKYN work?
This therapy involves modifying the patient's own skin cells to produce functional type VII collagen, essential for skin integrity and healing wounds associated with RDEB.
What are the potential side effects of ZEVASKYN?
Patients may experience allergic reactions, pain at the treatment site, and the risk of serious complications like anaphylaxis. Continuous monitoring for any signs of cancer is advised.
Where is the new treatment center located?
The newest Qualified Treatment Center for ZEVASKYN is located at Children's Hospital Colorado in Aurora.
How can patients access Abeona Assist services?
Patients can learn more about Abeona Assist by visiting the official Abeona Therapeutics website or by contacting their support line directly for personalized assistance.
